Nevertheless, since the goal of our study was to investigate whether improvement in NASH would be accompanied by modulation of KLF10 expression, UDCA was used as a safe means of investigation. The gene discussed is KLF10; the disease is metabolic dysfunction-associated steatohepatitis.